Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2006

View Archived Issues

YM-341619: novel STAT-6 inhibitor with efficacy against allergy

University of Arizona presents a novel bifunctional opioid agonist/NK-1 antagonist

Antiendotoxic effects of a novel polymyxin B analogue

Evidence connects chemokines and their receptors with lung metastasis

Alnylam's pandemic influenza research boosted by NIAID grant

Intercell and Path team up for S. pneumoniae vaccine

SBIR grant for Cleveland BioLabs' radioprotector research

MethylGene report on enhanced potency of second generation MGCD-0103 analogues

Artisan Pharma formed through financing and compound inlicensing

p53/p21 status regulates the response to VX-680

Italian researchers present a novel selective muscarinic M3 receptor antagonist

Dual dopamine D2/D3 receptor ligand described with antipsychotic efficacy

European orphan designation for Advexin in Li-Fraumeni syndrome

Ipsen and GTx sign European agreement for Acapodene rights

Phase IIb studies in Denmark to assess BP-C1 for breast cancer

Taisho and Tokuhon collaborate on antiinflammatory analgesic patch in Japan

Takara Bio offers RetroNectin for phase I CLL trials

AnGes plans atopic dermatitis trial for NF-kappaB decoy oligodeoxynucleotide

Northwest cleared for phase I study of DCVax-LB in NSCLC

Xoma successfully reformulates XOMA-629 for acne

New ARIES-3 study investigates ambrisentan in pulmonary hypertension

Chelsea seeks orphan drug status, forms scientific advisory board for droxidopa

Teverelix LA shows potential for endometriosis

Novel antiinfective agents disclosed in recent patent literature

Symlin improves diabetes control in study

Recent patents disclose new therapeutic agents for depression, insomnia

Novel diagnostic agents emerge from Mallinckrodt R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...